GTC Biotherapeutics (fka GTCB)

[DewDiligence]

PIP expects to submit the Protexia IND in 3Q08 and start a phase-1 trial in 4Q08 (#msg-27390930). Hence, PIP’s manufacturing process—and the need for GTC’s consultation—ought to be complete by then.

If Protexia makes it to market, GTC stands to earn a small royalty on sales (#msg-27957879, bottom).